InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,242.40
(
1.56%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.02%
)
Bitcoin
63,799.58
(
-1.07%
)
Post# of 160314
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jaybird249

Send PM Follow Ignore
Followers 82
Posts 2822
Boards Moderated 0
Alias Born 05/05/2006

jaybird249

Re: None

Thursday, 05/26/2011 11:44:20 AM

Thursday, May 26, 2011 11:44:20 AM

Post# of 160314
RXII $1.01 +.03 30 MM market cap ASCO Cancer vaccine Blockbuster results
I called OXGN at $1.80. I think RXII is the next special situation biotech that could triple in a very short time frame. RXII has one of the most promising cancer vaccines, with SPA status and a potential $5 billion market.

RXII has been undiscovered but not for long. RXII CANCER VACCINE REDUCED BREAST CANCER RECURRANCE FROM 14% TO 2% (2 YEARS OF DATA). 3 year results presented at ASCO.

RXII has $20 MM cash and a $30 MM market cap, meaning the market is valuing its technology at $10 million.
Other junior biotechs in the cancer vaccine space like AGEN:NASDAQ have minimum $100 MM ++ market caps.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up